Ethic Inc. raised its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK – Free Report) by 19.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 436,514 shares of the company’s stock after buying an additional 71,261 shares during the quarter. Ethic Inc.’s holdings in Takeda Pharmaceutical were worth $7,940,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. May Hill Capital LLC bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $256,000. Commonwealth Equity Services LLC boosted its stake in Takeda Pharmaceutical by 20.7% in the third quarter. Commonwealth Equity Services LLC now owns 27,282 shares of the company’s stock valued at $496,000 after acquiring an additional 4,684 shares in the last quarter. Ascent Group LLC boosted its stake in Takeda Pharmaceutical by 19.5% in the third quarter. Ascent Group LLC now owns 19,996 shares of the company’s stock valued at $364,000 after acquiring an additional 3,262 shares in the last quarter. Pzena Investment Management LLC boosted its stake in Takeda Pharmaceutical by 19.8% in the third quarter. Pzena Investment Management LLC now owns 45,310 shares of the company’s stock valued at $824,000 after acquiring an additional 7,490 shares in the last quarter. Finally, Provenance Wealth Advisors LLC purchased a new position in Takeda Pharmaceutical in the third quarter worth $27,000. 9.17% of the stock is currently owned by institutional investors.
Takeda Pharmaceutical Stock Performance
TAK opened at $21.02 on Monday. Takeda Pharmaceutical Co. has a 52-week low of $13.56 and a 52-week high of $21.73. The company has a quick ratio of 0.60, a current ratio of 1.15 and a debt-to-equity ratio of 0.56. The company has a market cap of $67.35 billion, a P/E ratio of 27.65 and a beta of -0.02. The firm’s 50-day moving average price is $19.12 and its 200-day moving average price is $17.67.
Insider Activity at Takeda Pharmaceutical
Analysts Set New Price Targets
TAK has been the topic of a number of recent analyst reports. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Weiss Ratings upgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, November 3rd. Finally, Zacks Research raised Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Takeda Pharmaceutical presently has a consensus rating of “Buy”.
Check Out Our Latest Stock Analysis on TAK
About Takeda Pharmaceutical
Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo.
The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.
Takeda serves patients and healthcare providers in Japan and markets around the world.
Further Reading
- Five stocks we like better than Takeda Pharmaceutical
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
